Glovadalen, a novel D1 receptor positive allosteric modulator, is linked to improve OFF time in patients with Parkinson’s ...

New study uses state-of-the-art technology to examine link between gene mutation and neurodegenerative disease A University of Wollongong ...

LAHORE: The Ministry of Planning, Development and Special Initiatives (PD&SI) has outlined a roadmap to accelerate the ...

Camrelizumab and famitinib are projected to achieve global annual sales of $463 million and $108 million by 2031.

A new study led by Rice University's Pernilla Wittung-Stafshede has revealed that protein clumps, or plaques that clog the brain, associated with ...

There is zero doubt that the word on everyone’s lips right now is Artificial Intelligence (AI); adoption, the benefits and ...

A label expansion for Keytruda in platinum-resistant ovarian cancer would further entrench MSD’s dominance in the PD-1 space.

A CPS source says legal experts are entitled to offer an opinion ‘based on published documents and media reports’.

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...

The FDA has approved Libtayo for the adjuvant treatment of adult patients with CSCC at high risk of recurrence after surgery and radiation.

Dato-DXd showed a 43% reduction in disease progression risk and a 21% reduction in death risk compared to chemotherapy in TNBC patients ineligible for immunotherapy. The TROPION-Breast02 trial ...